RTTNews | Jun 7, 2021 09:55AM EDT

09:54 Monday, June 7, 2021 (RTTNews.com) - Shares of bluebird bio Inc. (BLUE) are currently trading at $31.42, up 50 cents or 1.62%, with trading volume of over 698K versus an average volume of 1.40 million shares. The stock has been trading in the range of $24.24 - $72.30 for the past one year.

bluebird bio announced that the U.S. FDA has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease or SCD gene therapy (bb1111) for adult and pediatric patients with SCD.

The FDA also lifted hold on the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies of betibeglogene autotemcel gene therapy (beti-cel; licensed as ZYNTEGLO in the EU and the UK) for adult, adolescent and pediatric patients with transfusion-dependent -thalassemia (TDT). The company is working closely with study investigators and clinical trial sites to resume all study activities as soon as possible.

Read the original article on RTTNews ( https://www.rttnews.com/3200447/blue-shares-up-after-fda-lifts-clinical-hold-for-sickle-cell-disease--thalassemia-studies.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved